Selinexor
KCP-330-008
Phase 2 small_molecule completed
Quick answer
Selinexor for Acute Myeloid Leukemia (AML) is a Phase 2 program (small_molecule) at Karyopharm Therapeutics with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Karyopharm Therapeutics
- Indication
- Acute Myeloid Leukemia (AML)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed